Opportunity Information: Apply for PA 16 233
Apply for PA 16 233
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Prescription Drug Abuse (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279,.
- This funding opportunity was created on May 10, 2016 and posted on May 10, 2016.
- Applicants must submit their applications by May 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Prescription Drug Abuse (R01) funding opportunity (PA-16-233) is a National Institutes of Health (NIH) research grant announcement under HHS that supports innovative, investigator-driven studies focused on understanding and reducing prescription drug abuse. The core purpose is to spur research that goes beyond documenting the problem and instead explains why prescription drug abuse happens, what harms it causes, who is most affected, and which prevention and treatment strategies actually work in real-world settings. The FOA is deliberately broad, inviting projects that can generate practical, evidence-based approaches to prevention, service delivery, and both behavioral and pharmacological treatments.
A major emphasis is on identifying and analyzing the factors that contribute to prescription drug abuse at multiple levels. The announcement encourages studies that look at individual and patient-level risks (such as clinical history, psychiatric symptoms, pain conditions, or substance use trajectories), but it also welcomes research on prescriber behaviors and decision-making, as well as health system influences such as clinical workflows, prescribing policies, monitoring programs, access to care, and other structural drivers. In other words, the FOA is meant to support research that can connect the dots between personal vulnerability, clinical practice, and the broader healthcare environment.
The FOA also prioritizes a clear, detailed characterization of the problem itself. Applicants are encouraged to define the extent of prescription drug abuse and describe it by drug class and patterns of use, including combinations of drug types. This includes attention to the etiology of abuse (how it develops over time), the adverse consequences that follow (medical outcomes, mental health impacts, and social harms), and the populations most affected. The announcement explicitly encourages analyses by age group, race and ethnicity, gender, and psychiatric symptomatology, reflecting an interest in understanding both disparities and subgroup-specific risk profiles that could shape targeted interventions.
In terms of substances, the opportunity is not limited to one medication category. It explicitly calls out multiple classes of prescription drugs with high abuse liability, including analgesics (commonly opioid pain medications), stimulants, sedative/hypnotics, and anxiolytics. This wide scope allows applicants to address prescription drug abuse as a multi-drug issue, including the important reality that misuse often involves polydrug patterns rather than a single medication type in isolation.
Another key theme is the relationship between the medication and the reason it was prescribed. The FOA encourages research that examines how the underlying indication (for example, pain, sleep disorders, anxiety disorders, or obesity) interacts with environmental and individual factors to increase or decrease risk of misuse. This framing supports studies that distinguish appropriate medical use from risky use patterns and that explore how clinical needs, symptom management, and contextual pressures can shape pathways toward misuse or dependence.
Methodologically, the FOA is intentionally inclusive. It supports a broad range of approaches, including basic science, clinical research, epidemiology, and health services research. That means projects could range from mechanistic or translational work to population-level surveillance and trend analysis, clinical trials of interventions, implementation studies in healthcare settings, or evaluations of service delivery models designed to prevent misuse and improve treatment engagement and outcomes.
Administratively, this is a discretionary grant using the NIH R01 mechanism, tied to CFDA numbers 93.279. Eligibility is broad and includes many organization types: state, county, and local governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses); small businesses; and other entities as described in the full eligibility text. The opportunity was posted and created on May 10, 2016, with an original and current closing date of May 7, 2019. Award ceiling and expected number of awards are not specified in the provided source details, which is common for some NIH program announcements where budgets depend on project scope and institute priorities.
Overall, the grant opportunity is designed to advance the science of prescription drug abuse in a way that can inform prevention, clinical practice, and health system responses. It encourages work that pinpoints drivers of misuse, clarifies the real-world consequences, identifies at-risk groups with appropriate demographic and clinical detail, and tests strategies that can reduce harm and improve care delivery across multiple drug classes and patient populations.
Frequently Asked Questions (FAQs): Prescription Drug Abuse (R01) - PA-16-233
What is the Prescription Drug Abuse (R01) funding opportunity (PA-16-233)?
PA-16-233 is a National Institutes of Health (NIH) research grant announcement under the U.S. Department of Health and Human Services (HHS). It uses the NIH R01 mechanism to support innovative, investigator-driven research focused on understanding and reducing prescription drug abuse.
What is the main purpose of this FOA?
The core purpose is to spur research that goes beyond simply documenting prescription drug abuse. The FOA emphasizes studies that explain why prescription drug abuse happens, what harms it causes, who is most affected, and which prevention and treatment strategies work in real-world settings.
What types of research questions does the FOA encourage?
The FOA encourages research that can connect causes, consequences, affected populations, and effective responses. This includes identifying drivers of misuse, describing patterns and trends, understanding how abuse develops over time, and evaluating prevention and treatment approaches that are practical and evidence-based.
Is the scope of this opportunity narrow or broad?
The FOA is deliberately broad. It invites a wide range of projects as long as they are focused on understanding and reducing prescription drug abuse and can generate knowledge that informs prevention, service delivery, or treatment strategies.
Which levels of influence are applicants encouraged to study?
The announcement emphasizes multi-level factors, including:
- Individual and patient-level risks (for example, clinical history, psychiatric symptoms, pain conditions, or substance use trajectories)
- Prescriber behaviors and decision-making
- Health system influences (for example, clinical workflows, prescribing policies, monitoring programs, access to care, and other structural drivers)
Does the FOA support studies on prescriber behavior and healthcare systems?
Yes. In addition to individual risk factors, the FOA explicitly welcomes research on prescriber behaviors and decision-making, as well as health system drivers such as policies, workflows, monitoring programs, and access to care.
What does the FOA mean by characterizing the problem "in detail"?
The FOA encourages applicants to define the extent of prescription drug abuse and describe it by drug class and patterns of use. This includes examining how abuse develops over time (etiology), the adverse consequences that follow, and identifying which populations are most affected.
Are applicants expected to analyze prescription drug abuse by demographic groups?
Yes. The FOA explicitly encourages analyses by age group, race and ethnicity, gender, and psychiatric symptomatology. This reflects an interest in understanding disparities and subgroup-specific risk profiles that can support targeted interventions.
What types of harms or consequences are relevant under this FOA?
The opportunity highlights adverse consequences of prescription drug abuse including medical outcomes, mental health impacts, and social harms.
Which prescription drug classes are included?
The FOA is not limited to a single drug category. It explicitly calls out multiple classes of prescription drugs with high abuse liability, including:
- Analgesics (commonly opioid pain medications)
- Stimulants
- Sedative/hypnotics
- Anxiolytics
Does the FOA allow research on polydrug use (combinations of drug types)?
Yes. The FOA encourages describing patterns of use, including combinations of drug types, recognizing that misuse often involves polydrug patterns rather than a single medication type.
Can studies focus on the relationship between a medication and the reason it was prescribed?
Yes. A key theme is the relationship between the medication and its underlying indication. The FOA encourages research on how the reason for prescribing (for example, pain, sleep disorders, anxiety disorders, or obesity) interacts with individual and environmental factors to influence misuse risk.
Does the FOA distinguish appropriate medical use from risky use patterns?
It supports research that examines how clinical needs, symptom management, and contextual pressures shape pathways toward misuse or dependence, which can help clarify distinctions between appropriate use and risky patterns.
What research methods or disciplines are supported?
The FOA is methodologically inclusive and supports a broad range of approaches, including basic science, clinical research, epidemiology, and health services research.
What kinds of study designs or project types fit within this FOA?
Based on the description, potential project types may include mechanistic or translational work, population-level surveillance and trend analyses, clinical trials of interventions, implementation studies in healthcare settings, or evaluations of service delivery models designed to prevent misuse and improve treatment engagement and outcomes.
What grant mechanism is used for this opportunity?
This opportunity uses the NIH R01 research project grant mechanism.
Is this a discretionary grant?
Yes. The opportunity is described as a discretionary grant using the NIH R01 mechanism.
What is the CFDA number associated with this opportunity?
The CFDA number provided is 93.279.
Who is eligible to apply?
Eligibility is broad and includes many organization types, including:
- State, county, and local governments
- Special district governments
- Independent school districts
- Public and private institutions of higher education
- Federally recognized tribal governments and other tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofits with and without 501(c)(3) status
- For-profit organizations (other than small businesses)
- Small businesses
- Other entities as described in the full eligibility text
Are for-profit organizations allowed to apply?
Yes. The eligibility list includes for-profit organizations (other than small businesses) and also separately includes small businesses.
Are tribal governments and tribal organizations eligible?
Yes. Federally recognized tribal governments and other tribal organizations are included in the eligibility list.
Are nonprofits without 501(c)(3) status eligible?
Yes. The eligibility description includes nonprofits with and without 501(c)(3) status.
Is the award ceiling specified?
No. The award ceiling is not specified in the provided details.
Is the expected number of awards specified?
No. The expected number of awards is not specified in the provided details.
When was this opportunity posted and created?
The opportunity was posted and created on May 10, 2016.
What was the closing date for this opportunity?
The original and current closing date provided is May 7, 2019.
What kinds of outcomes is this FOA trying to achieve?
The opportunity is designed to advance the science of prescription drug abuse in ways that inform prevention, clinical practice, and health system responses. It emphasizes pinpointing drivers of misuse, clarifying consequences, identifying at-risk groups with demographic and clinical detail, and testing strategies that reduce harm and improve care delivery.
Browse more opportunities from the same agency: HHS-NIH11
Browse more opportunities from the same category: Education, Health
Next opportunity: Gene Fusions in Pediatric Sarcomas (R01)
Previous opportunity: M&E Toolkit: OCFT Sector-Specific Interventions and Cross-Cutting Themes
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 233
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 233) also looked into and applied for these:
| Funding Opportunity |
|---|
| Gene Fusions in Pediatric Sarcomas (R01) Apply for PA 16 251 Funding Number: PA 16 251 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Innovative Approaches to Studying Cancer Communication in the New Media Environment (R01) Apply for PAR 16 249 Funding Number: PAR 16 249 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Gene Fusions in Pediatric Sarcomas (R21) Apply for PA 16 252 Funding Number: PA 16 252 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Innovative Approaches to Studying Cancer Communication in the New Media Environment (R21) Apply for PAR 16 248 Funding Number: PAR 16 248 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01) Apply for PAR 16 234 Funding Number: PAR 16 234 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Building Evidence: Effective Palliative/End of Life Care Interventions (R01) Apply for PAR 16 250 Funding Number: PAR 16 250 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21) Apply for PAR 16 257 Funding Number: PAR 16 257 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Cancer-related Behavioral Research through Integrating Existing Data (R21) Apply for PAR 16 255 Funding Number: PAR 16 255 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Cancer-related Behavioral Research through Integrating Existing Data (R01) Apply for PAR 16 256 Funding Number: PAR 16 256 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Methodology and Measurement in the Behavioral and Social Sciences (R01) Apply for PAR 16 260 Funding Number: PAR 16 260 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21) Apply for PA 16 258 Funding Number: PA 16 258 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Methodology and Measurement in the Behavioral and Social Sciences (R21) Apply for PAR 16 261 Funding Number: PAR 16 261 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01) Apply for PAR 16 266 Funding Number: PAR 16 266 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Serious Adverse Drug Reaction Research (R21) Apply for PAR 16 274 Funding Number: PAR 16 274 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Serious Adverse Drug Reaction Research (R01) Apply for PAR 16 275 Funding Number: PAR 16 275 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01) Apply for PAR 16 276 Funding Number: PAR 16 276 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43) Apply for PAR 16 279 Funding Number: PAR 16 279 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $280,000 |
| Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11) Apply for PAR 16 280 Funding Number: PAR 16 280 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $92,000 |
| Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21) Apply for PAR 16 278 Funding Number: PAR 16 278 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Prescription Drug Abuse (R21) Apply for PA 16 232 Funding Number: PA 16 232 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 233", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.